Anteris Technologies Global (NASDAQ:AVR) Upgraded at Barclays

Key Points

• Barclays upgraded Anteris Technologies Global to “hold.” The stock has an average analyst rating of “Hold” and an average price target of $14, compared with a recent price of $6.82.
• Quarterly results fell short of expectations: the company reported a $0.30-per-share loss versus a projected $0.21 loss, while revenue of $1.01 million missed the $1.50 million consensus estimate.
• Major shareholder L1 Capital increased its position. It purchased 648,455 shares for approximately $4.87 million, although insiders collectively sold more shares than they bought over the past 90 days.

Anteris Technologies Global (NASDAQ:AVR - Get Free Report) was upgraded by investment analysts at Barclays to a "hold" rating in a research report issued on Wednesday, Zacks reports.

A number of other analysts have also recently commented on AVR. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $15.00 price target on shares of Anteris Technologies Global in a research note on Friday, August 14th. Weiss Ratings reissued a "sell (d-)" rating on shares of Anteris Technologies Global in a research note on Wednesday, August 26th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $14.00.

Anteris Technologies Global Stock Down 3.3%

Shares of Anteris Technologies Global stock opened at $6.82 on Wednesday. Anteris Technologies Global has a 12 month low of $3.30 and a 12 month high of $11.06. The business has a fifty day simple moving average of $8.44 and a 200 day simple moving average of $8.02. The stock has a market cap of $664.68 million, a PE ratio of -3.50 and a beta of 1.87.

Anteris Technologies Global (NASDAQ:AVR - Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.09). Anteris Technologies Global had a negative net margin of 4,619.27% and a negative return on equity of 77.69%. The company had revenue of $1.01 million during the quarter, compared to the consensus estimate of $1.50 million. During the same quarter in the prior year, the company posted ($0.58) EPS. Analysts expect that Anteris Technologies Global will post -1.21 EPS for the current fiscal year.

Insider Activity

In other Anteris Technologies Global news, major shareholder L1 Capital Pty Ltd purchased 648,455 shares of the company's stock in a transaction dated Monday, October 5th. The shares were bought at an average price of $7.51 per share, with a total value of $4,869,897.05. Following the completion of the transaction, the insider directly owned 12,778,380 shares in the company, valued at $95,965,633.80. This trade represents a 5.35% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last ninety days, insiders bought 1,282,035 shares of company stock valued at $9,736,563 and sold 3,008,459 shares valued at $25,243,576. 4.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Anteris Technologies Global

Institutional investors and hedge funds have recently modified their holdings of the business. Abel Hall LLC bought a new stake in Anteris Technologies Global during the 1st quarter worth approximately $63,000. J. Derek Lewis & Associates Inc. bought a new position in Anteris Technologies Global in the fourth quarter valued at approximately $70,000. Legal & General Group Plc acquired a new position in shares of Anteris Technologies Global in the second quarter valued at approximately $78,000. Bartlett & CO. Wealth Management LLC boosted its holdings in shares of Anteris Technologies Global by 174.5% in the first quarter. Bartlett & CO. Wealth Management LLC now owns 12,900 shares of the company's stock valued at $79,000 after buying an additional 8,200 shares during the period. Finally, Cetera Investment Advisers increased its position in shares of Anteris Technologies Global by 64.7% during the first quarter. Cetera Investment Advisers now owns 16,550 shares of the company's stock worth $92,000 after acquiring an additional 6,500 shares in the last quarter.

Anteris Technologies Global News Summary

Here are the key news stories impacting Anteris Technologies Global this week:

• Positive Sentiment: Major shareholder made substantial purchases. L1 Capital Pty Ltd bought 648,455 AVR shares on October 5 at an average of $7.51, worth approximately $4.87 million, increasing its position by 5.35% to 12.78 million shares. The investor also purchased 236,354 shares on October 2 for about $1.84 million. The buying may bolster confidence because a large shareholder is committing additional capital while the stock is trading below recent moving averages. AVR insider buying report
• Neutral Sentiment: Share and incentive records were updated. Anteris reported a slight decrease in CHESS Depositary Interests and the lapse or cessation of several restricted stock unit and option tranches. These changes could affect the share count and potential dilution, but no new operating, clinical, or regulatory catalyst was announced. AVR CDI and equity incentive update
• Negative Sentiment: Financial performance remains weak. Anteris’ latest quarterly loss of $0.30 per share was wider than the $0.21 consensus estimate, while revenue of $1.01 million trailed expectations of $1.50 million. The clinical-stage structural-heart company remains unprofitable, with analysts expecting a full-year loss, factors that continue to weigh on valuation and investor sentiment. AVR earnings and performance report

About Anteris Technologies Global

Anteris Technologies Global is a clinical-stage structural heart company developing technologies intended to treat aortic valve disease. The company's lead product is the DurAVR transcatheter heart valve, which is designed to replicate the performance characteristics of a healthy human aortic valve and restore more natural blood flow.

Anteris uses its proprietary ADAPT tissue-engineering technology to create heart-valve materials designed for durability and biocompatibility. The company is focused primarily on transcatheter aortic valve replacement and related structural-heart applications, with its products progressing through clinical development and regulatory evaluation rather than broad commercial distribution.

The company has Australian origins and maintains operations and clinical-development activities in both Australia and the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.